A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity.
Research output: Contribution to journal › Article
Standard
A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity. / Welinder, Charlotte; Baldetorp, Bo; Borrebaeck, Carl; Fredlund, Britt-Marie; Jansson, Bo.
In: Glycobiology, Vol. 21, No. 8, 2011, p. 1097-1107.Research output: Contribution to journal › Article
Harvard
APA
CBE
MLA
Vancouver
Author
RIS
TY - JOUR
T1 - A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity.
AU - Welinder, Charlotte
AU - Baldetorp, Bo
AU - Borrebaeck, Carl
AU - Fredlund, Britt-Marie
AU - Jansson, Bo
PY - 2011
Y1 - 2011
N2 - The Tn antigen (GalNAc alpha-O-Ser/Thr) is heterogeneously synthesised by a variety of tumours and contains an epitope defined by lectins and antibodies as a cluster of alpha GalNAc carbohydrates synthesised within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridisation after immunisation of a mouse with a tumour cell line and a Tn carrying mucin. The antibody recognises synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has ADCC activity against Jurkat cells in vitro and for the first time it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in SCID mice.
AB - The Tn antigen (GalNAc alpha-O-Ser/Thr) is heterogeneously synthesised by a variety of tumours and contains an epitope defined by lectins and antibodies as a cluster of alpha GalNAc carbohydrates synthesised within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridisation after immunisation of a mouse with a tumour cell line and a Tn carrying mucin. The antibody recognises synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has ADCC activity against Jurkat cells in vitro and for the first time it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in SCID mice.
KW - monoclonal antibody
KW - in vivo therapy
KW - antigen
KW - Tn
KW - anti-carbohydrate
KW - biomarker
U2 - 10.1093/glycob/cwr048
DO - 10.1093/glycob/cwr048
M3 - Article
C2 - 21470982
VL - 21
SP - 1097
EP - 1107
JO - Glycobiology
JF - Glycobiology
SN - 1460-2423
IS - 8
ER -